Back

Real-world burden of heart failure with reduced ejection fraction and dapagliflozin use at 2 years after approval in 9 countries from Central Eastern Europe and Baltic Area: EVOLUTION-HF CEE-BA study

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Digitoxin and other therapeutic strategic advances Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Professor Ivan Gruev

National Transport Hospital Tzar Boris III, Sofia (Bulgaria)

4 More presentations in this session

Presentation thumbnail
Effects of glucagon like peptide 1 receptor agonist initiation in patients with heart failure and reduced ejection fraction and implantable cardiac devices
Doctor P. Marques (Porto, PT)
Abstract Slides Video
Presentation thumbnail
Hemoglobin, hematocrit and heart failure: the SGLT2 inhibitor connection
Doctor D. Ferreira (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of early initiation of mineralocorticoid receptor antagonists in patients with worsening heart failure: a meta-analysis of randomized controlled trials
Doctor R. Laborante (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Socioeconomic disparities in guideline directed medical therapy for HFrEF: a population-based cohort study using electronic health records (the Netherlands)
Ms J. van Eijk (Utrecht, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Digitoxin and other therapeutic strategic advances

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Clinical characteristics and treatment patterns of new users of dapagliflozin for heart failure with reduced ejection fraction: an observational study programme across 12 countries (EVOLUTION HF)
thumbnail
Congress Presentation
Evaluation of the effects of the Sodium-glucose cotransporter 2 inhibitors and sacubitril/valsartan combined therapy in patients with HFrEF: echocardiographic study.
thumbnail
Congress Presentation
Residual risk of hospitalization & all-cause mortality among patients with heart failure with reduced ejection fraction without worsening heart failure who received guideline-directed medical therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources